SEARCH

SEARCH BY CITATION

References

  • Abramovitz M., Adam M., Boie Y. et al. (2000) The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim. Biophys. Acta 1483, 285293.
  • Akanuma S., Hosoya K., Ito S., Tachikawa M., Terasaki T. and Ohtsuki S. (2010) Involvement of multidrug resistance-associated protein 4 in efflux transport of prostaglandin E(2) across mouse blood-brain barrier and its inhibition by intravenous administration of cephalosporins. J. Pharmacol. Exp. Ther. 333, 912919.
  • Aquilante C. L., Letrent S. P., Pollack G. M. and Brouwer K. L. (2000) Increased brain P-glycoprotein in morphine tolerant rats. Life Sci. 66, PL47PL51.
  • Asboth G., Phaneuf S., Europe-Finner G. N., Toth M. and Bernal A. L. (1996) Prostaglandin E2 activates phospholipase C and elevates intracellular calcium in cultured myometrial cells: involvement of EP1 and EP3 receptor subtypes. Endocrinology 137, 25722579.
  • Bauer B., Hartz A. M., Pekcec A., Toellner K., Miller D. S. and Potschka H. (2008) Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol. Pharmacol. 73, 14441453.
  • Bentires-Alj M., Barbu V., Fillet M., Chariot A., Relic B., Jacobs N., Gielen J., Merville M. P. and Bours V. (2003) NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22, 9097.
  • Callaghan R. and Riordan J. R. (1993) Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. J. Biol. Chem. 268, 1605916064.
  • Campa D., Gioia A., Tomei A., Poli P. and Barale R. (2008) Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin. Pharmacol. Ther. 83, 559566.
  • Chen Y. J., Huang W. C., Wei Y. L. et al. (2011) Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. PLoS ONE 6, e21428.
  • Dagenais C., Graff C. L. and Pollack G. M. (2004) Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem. Pharmacol. 67, 269276.
  • Dauchy S., Dutheil F., Weaver R. J., Chassoux F., Daumas-Duport C., Couraud P. O., Scherrmann J. M., De Waziers I. and Decleves X. (2008) ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J. Neurochem. 107, 15181528.
  • Dauchy S., Miller F., Couraud P. O., Weaver R. J., Weksler B., Romero I. A., Scherrmann J. M., De Waziers I. and Decleves X. (2009) Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. Biochem. Pharmacol. 77, 897909.
  • Decleves X., Jacob A., Yousif S., Shawahna R., Potin S. and Scherrmann J. M. (2011) Interplay of drug metabolizing CYP450 enzymes and ABC transporters in the blood-brain barrier. Curr. Drug Metab. 12, 732741.
  • Degner F. T. D. and Pairet M. (1998) Pharmacological, pharmacokinetic and clinical profile of meloxicam. Drugs Today 34, 122.
  • Desjardins S., Belkai E., Crete D., Cordonnier L., Scherrmann J. M., Noble F. and Marie-Claire C. (2008) Effects of chronic morphine and morphine withdrawal on gene expression in rat peripheral blood mononuclear cells. Neuropharmacology 55, 13471354.
  • Engelhardt G. (1996) Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. Br. J. Rheumatol. 35, 412.
  • Fujino H., West K. A. and Regan J. W. (2002) Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. J. Biol. Chem. 277, 26142619.
  • Groenendaal D., Freijer J., de Mik D., Bouw M. R., Danhof M. and de Lange E. C. (2007) Influence of biophase distribution and P-glycoprotein interaction on pharmacokinetic-pharmacodynamic modelling of the effects of morphine on the EEG. Br. J. Pharmacol. 151, 713720.
  • Guo M., Xu N. J., Li Y. T., Yang J. Y., Wu C. F. and Pei G. (2005) Morphine modulates glutamate release in the hippocampal CA1 area in mice. Neurosci. Lett. 381, 1215.
  • Hamabe W., Maeda T., Fukazawa Y., Kumamoto K., Shang L. Q., Yamamoto A., Yamamoto C., Tokuyama S. and Kishioka S. (2006) P-glycoprotein ATPase activating effect of opioid analgesics and their P-glycoprotein-dependent antinociception in mice. Pharmacol. Biochem. Behav. 85, 629636.
  • Hata A. N. and Breyer R. M. (2004) Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol. Ther. 103, 147166.
  • Ito K., Uchida Y., Ohtsuki S., Aizawa S., Kawakami H., Katsukura Y., Kamiie J. and Terasaki T. (2011) Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. J. Pharm. Sci. 100, 39393950.
  • Kalivas P. W. and Duffy P. (1987) Sensitization to repeated morphine injection in the rat: possible involvement of A10 dopamine neurons. J. Pharmacol. Exp. Ther. 241, 204212.
  • Karin M. (1999) How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene 18, 68676874.
  • Kim H., Rhee S. H., Pothoulakis C. and Lamont J. T. (2007) Inflammation and apoptosis in Clostridium difficile enteritis is mediated by PGE2 up-regulation of Fas ligand. Gastroenterology 133, 875886.
  • King M., Su W., Chang A., Zuckerman A. and Pasternak G. W. (2001) Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs. Nat. Neurosci. 4, 268274.
  • Lee E. O., Shin Y. J. and Chong Y. H. (2004) Mechanisms involved in prostaglandin E2-mediated neuroprotection against TNF-alpha: possible involvement of multiple signal transduction and beta-catenin/T-cell factor. J. Neuroimmunol. 155, 2131.
  • Letrent S. P., Pollack G. M., Brouwer K. R. and Brouwer K. L. (1999) Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab. Dispos. 27, 827834.
  • Letrent S. P., Polli J. W., Humphreys J. E., Pollack G. M., Brouwer K. R. and Brouwer K. L. (1999) P-glycoprotein-mediated transport of morphine in brain capillary endothelial cells. Biochem. Pharmacol. 58, 951957.
  • Lim J. C., Kania K. D., Wijesuriya H. et al. (2008) Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J. Neurochem. 106, 18551865.
  • Lotsch J., von Hentig N., Freynhagen R., Griessinger N., Zimmermann M., Doehring A., Rohrbacher M., Sittl R. and Geisslinger G. (2009) Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet. Genomics 19, 429436.
  • Miller D. S. (2010) Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol. Sci. 31, 246254.
  • Muller C., Laurent G. and Ling V. (1995) P-glycoprotein stability is affected by serum deprivation and high cell density in multidrug-resistant cells. J. Cell. Physiol. 163, 538544.
  • Pajic M., Bebawy M., Hoskins J. M., Roufogalis B. D. and Rivory L. P. (2004) Effect of short-term morphine exposure on P-glycoprotein expression and activity in cancer cell lines. Oncol. Rep. 11, 10911095.
  • Pal D., Kwatra D., Minocha M., Paturi D. K., Budda B. and Mitra A. K. (2011) Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals. Life Sci. 88, 959971.
  • Pekcec A., Unkruer B., Schlichtiger J., Soerensen J., Hartz A. M., Bauer B., van Vliet E. A., Gorter J. A. and Potschka H. (2009) Targeting prostaglandin E2 EP1 receptors prevents seizure-associated P-glycoprotein up-regulation. J. Pharmacol. Exp. Ther. 330, 939947.
  • Peng H., Qi J., Dong Z. and Zhang J. T. (2010) Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells. PLoS ONE 5, e15276.
  • Potschka H. (2010) Modulating P-glycoprotein regulation: future perspectives for pharmacoresistant epilepsies? Epilepsia 51, 13331347.
  • Reid G., Wielinga P., Zelcer N., van der Heijden I., Kuil A., de Haas M., Wijnholds J. and Borst P. (2003) The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc. Natl Acad. Sci. USA 100, 92449249.
  • Saubamea B., Cochois-Guegan V., Cisternino S. and Scherrmann J. M. (2012) Heterogeneity in the rat brain vasculature revealed by quantitative confocal analysis of endothelial barrier antigen and P-glycoprotein expression. J. Cereb. Blood Flow Metab. 32, 8192.
  • Scherrmann J. M. (2005) Expression and function of multidrug resistance transporters at the blood-brain barriers. Expert Opin. Drug Metab. Toxicol. 1, 233246.
  • Schinkel A. H., Wagenaar E., van Deemter L., Mol C. A. and Borst P. (1995) Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96, 16981705.
  • Scotto K. W. (2003) Transcriptional regulation of ABC drug transporters. Oncogene 22, 74967511.
  • Sepulveda J., Oliva P. and Contreras E. (2004) Neurochemical changes of the extracellular concentrations of glutamate and aspartate in the nucleus accumbens of rats after chronic administration of morphine. Eur. J. Pharmacol. 483, 249258.
  • Shawahna R., Uchida Y., Decleves X. et al. (2011) Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol. Pharm. 8, 13321341.
  • Thompson S. J., Koszdin K. and Bernards C. M. (2000) Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 92, 13921399.
  • Tomimoto H., Shibata M., Ihara M., Akiguchi I., Ohtani R. and Budka H. (2002) A comparative study on the expression of cyclooxygenase and 5-lipoxygenase during cerebral ischemia in humans. Acta Neuropathol. 104, 601607.
  • Tournier N., Chevillard L., Megarbane B., Pirnay S., Scherrmann J. M. and Decleves X. (2010) Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int. J. Neuropsychopharmacol. 13, 905915.
  • Tournier N., Decleves X., Saubamea B., Scherrmann J. M. and Cisternino S. (2011) Opioid transport by ATP-binding cassette transporters at the blood-brain barrier: implications for neuropsychopharmacology. Curr. Pharm. Des. 17, 28292842.
  • Urquhart B. L. and Kim R. B. (2009) Blood-brain barrier transporters and response to CNS-active drugs. Eur. J. Clin. Pharmacol. 65, 10631070.
  • de Vries N. A., Buckle T., Zhao J., Beijnen J. H., Schellens J. H. and van Tellingen O. (2012) Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest. New Drugs 30, 443449.
  • Way E. L., Loh H. H. and Shen F. H. (1969) Simultaneous quantitative assessment of morphine tolerance and physical dependence. J. Pharmacol. Exp. Ther. 167, 18.
  • Weksler B. B., Subileau E. A., Perriere N. et al. (2005) Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 19, 18721874.
  • Yousif S., Marie-Claire C., Roux F., Scherrmann J. M. and Decleves X. (2007) Expression of drug transporters at the blood-brain barrier using an optimized isolated rat brain microvessel strategy. Brain Res. 1134, 111.
  • Yousif S., Saubamea B., Cisternino S., Marie-Claire C., Dauchy S., Scherrmann J. M. and Decleves X. (2008) Effect of chronic exposure to morphine on the rat blood-brain barrier: focus on the P-glycoprotein. J. Neurochem. 107, 647657.
  • Zastre J. A., Chan G. N., Ronaldson P. T., Ramaswamy M., Couraud P. O., Romero I. A., Weksler B., Bendayan M. and Bendayan R. (2009) Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J. Neurosci. Res. 87, 10231036.
  • Zhu H. J. and Liu G. Q. (2004) Glutamate up-regulates P-glycoprotein expression in rat brain microvessel endothelial cells by an NMDA receptor-mediated mechanism. Life Sci. 75, 13131322.
  • Zibell G., Unkruer B., Pekcec A., Hartz A. M., Bauer B., Miller D. S. and Potschka H. (2009) Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology 56, 849855.
  • Zong J. and Pollack G. M. (2000) Morphine antinociception is enhanced in mdr1a gene-deficient mice. Pharm. Res. 17, 749753.
  • Zong J. and Pollack G. M. (2003) Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin. J. Pharmacol. Exp. Ther. 306, 556562.